可手术的局部晚期非小细胞肺癌的新希望：新辅助免疫治疗

Promise of Neoadjuvant Immunotherapy in Resected Non-small Cell Lung Cancer

免疫检查点抑制剂(immune checkpoint inhibitor,ICI)已经成为晚期非小细胞肺癌治疗的重要手段之一。目前ICI在新辅助治疗阶段的使用还非常有限。然而在肿瘤免疫治疗的这个大背景下,新辅助免疫治疗可能有更突出的优势。在这篇综述中,我们会讨论一部分临床前研究以及免疫新辅助治疗临床研究结果,并探讨其可能的作用机制。我们还会特别指出新辅助免疫治疗的潜在危险和一部分需要解决的问题。

Immune checkpoint inhibitor(ICI)has been proven to be a major breakthrough in patients with advanced non-small cell lung cancer.Up to now,neoadjuvant therapy using ICI are rare.However,in the context of cancer immunotherapy,neoadjuvant treatment may offer an extra advantage.In this review,we will disscuss the existing preclinical data and emerging clinical findings in the neoadjuvant setting and its potential mechanism of action.We will also highlight the potential damage and the questions that are required to be answered.